New share issue of SEK 54 million provides basis for Quiatech to commercialize its products
New share issue of SEK 54 million provides basis for Quiatech to commercialize its products SEB Företagsinvest, Scandinavian Life Science Venture, Stiftelsen Industrifonden and InnovationsKapital invest SEK 54 million in Quiatech. Quiatech will use the proceeds from the new issue mainly to finalize its product development, as well as to commercialize its products. Founded in February 2000, Quiatech is focusing on developing technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics. Its products are based on technologies and patents developed by Associate